


Gone viral

Shares of Biolidics have swung in the last few months amid a series of rapid-fire announcements. Here is a timeline of recent events.



- 1 March 30:** Biolidics announces it is launching its Covid-19 rapid test kit by end April.
- 2 April 1:** It obtains authorisation for the use of test kits in the Philippines.
- 3 April 6:** Biolidics' test kits are allowed to be sold in the European Union.
- 4 April 13:** Biolidics announces plans to distribute its test kits in the US.
- 5 April 20:** Biolidics gets permission to market and sell its test kits in the US.
- 6 April 23:** Biolidics signs exclusive US distribution deal with Aytu Bioscience for its test kits.
- 7 April 26:** Biolidics responds to Singapore Exchange (SGX) queries over its appointment of scandal-hit Aytu that it does not expect the agreement to have a material impact on its business plans.
- 8 May 8:** Biolidics appoints Mediproud as the non-exclusive distributor of its test kits in Thailand.

- 9 May 11:** Biolidics appoints Clearbridge Health as non-exclusive regional distributor of its test kits in the Philippines, Indonesia, Myanmar and Vietnam.
- 10 June 27:** Biolidics calls off the sale of its test kits in the US, citing increased competition. It announces it is working with Aytu to develop a new test kit with broader use outside of laboratory or clinical settings.
- 11 July 3:** SGX queries Biolidics on its scrapped distribution deal with Aytu.
- 12 July 8:** Biolidics signs five-year agreement with China's LC-Bio to develop cancer-diagnostic solutions.
- 13 July 9:** Biolidics signs five-year licence agreement with Accelerate Technologies for the use of Covid-19 viral spike detection technology. It announces plans to develop new tests incorporating the technology.
- 14 July 14:** Biolidics announces the A*Star licence pact.
- 15 July 15:** SGX queries Biolidics on the timing and details of its A*Star licence announcement.